Biogen 2Q earnings preview: APLS consolidation impacts EPS, while 2H portfolio dynamics remain the key variable

Overview

This report is Goldman Sachs' preview of Biogen Inc.'s 2Q earnings. It notes that BIIB shares have outperformed the DRG and S&P 500 year-to-date and that 2Q is typically a stronger quarter for the company, but EPS this quarter will be affected by APLS acquisition-related IPR&D, R&D and selling expenses, financing costs, and foregone interest income. Goldman Sachs is more focused on management's commentary during the earnings call regarding MS franchise erosion, the new product cycle, pipeline progress, and APLS integration.

Core views

Goldman Sachs remains constructive on BIIB's medium-term positioning, primarily because several product and pipeline variables could develop around 2027: the APLS acquisition could contribute Syfovre and Empaveli revenue and generate synergies; subcutaneous Leqembi and blood-based diagnostics could improve the Alzheimer's treatment pathway; and felzartamab, litifilimab, and salanersen have important readouts ahead. However, the report also emphasizes that investor positioning and views are mixed, with several high-risk events in 2H, including litifilimab SLE Ph3 data and ANNX geographic atrophy Ph3 data.

Analysis framework

The report combines an earnings preview, product portfolio analysis, pipeline catalyst tracking, and DCF valuation. It compares Goldman Sachs' forecasts with market consensus and incorporates APLS acquisition expenses, synergies, financing costs, MS franchise decline, the Leqembi ramp pathway, and key clinical readouts into the investment assessment.

Methodology notes

• Valuation methodsDCF

  100% DCF valuation

  Goldman Sachs' 12-month price target of $271 is based on a 100% DCF analysis, using a 1% long-term growth rate and 9% WACC.

• fundamental_analysisEarnings preview

  Earnings preview

  The report forecasts 2Q revenue, non-GAAP EPS, APLS acquisition expenses, and subsequent guidance updates, while highlighting key topics for the earnings call.

• factor_profileGS Factor Profile

  Growth, financial returns, valuation multiples, and composite percentiles

  The disclosure section explains that Goldman Sachs' factor framework uses standardized rankings for growth, financial returns, and valuation multiples to provide investment context relative to the broader market and industry peers.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• BIIB.N

  Stock of the report subject company

  Strengths

  The APLS acquisition could drive 2027 EPS accretion; subcutaneous Leqembi, blood-based diagnostics, and expansion of the early Alzheimer's market represent potential growth drivers; felzartamab, litifilimab, and salanersen provide multiple medium-term catalysts.

  Weaknesses

  The legacy MS franchise continues to face generic and biosimilar erosion; diranersen Ph2 data remain subject to debate over dose response and statistical significance; near-term EPS is weighed down by IPR&D and transaction expenses.

  Comparison

  The report notes that BIIB has returned +3% vs. DRG and +2% vs. the S&P 500 year-to-date; KOLs view subcutaneous Leqembi as an important differentiator versus LLY's Kisunla.

  Risks

  Successful ANNX geographic atrophy Ph3 data could challenge Syfovre's value; LLY's Kisunla and TRAILBLAZER-ALZ 3 data in Alzheimer's disease could also affect the competitive landscape.

• Leqembi

  BIIB/Eisai Alzheimer's disease product

  Strengths

  Subcutaneous induction dosing has been approved; reimbursement in January 2027, subcutaneous maintenance and induction regimens, and broader adoption of blood-based biomarkers could relieve neurologist and infusion-center bottlenecks.

  Weaknesses

  Commercial ramp-up remains dependent on reimbursement, the diagnostic pathway, and physician adoption.

  Comparison

  KOLs view the subcutaneous formulation as a key differentiator versus LLY's Kisunla.

  Risks

  LLY preclinical Alzheimer's data and subsequent market competition could affect the long-term opportunity.

• Syfovre

  Geographic atrophy product brought in through the APLS acquisition

  Strengths

  An important component of post-APLS-acquisition revenue contribution and 2027 EPS accretion.

  Weaknesses

  Approximately $15 per share of value is already reflected in the valuation; deterioration in the competitive landscape could pressure the share price.

  Comparison

  ANNX's geographic atrophy Ph3 data are viewed as a potential competitive variable.

  Risks

  If ANNX data are successful, Goldman Sachs estimates that removing Syfovre's value would reduce DCF by 5.5%, corresponding to an approximately 8% downside impact on the current price.

Key data

• YTD relative performance+3% vs. DRG; +2% vs. S&P500The report states that BIIB has outperformed the pharmaceutical index and the S&P 500 year-to-date.
• 2Q revenue forecastGSe $2.51bn; FactSet consensus $2.45bnGoldman Sachs expects 2Q total revenue to be broadly in line with expectations.
• 2Q non-GAAP EPS forecastGSe $1.67; FactSet consensus $3.152Q EPS includes an approximately $0.95 per-share IPR&D expense impact related to the APLS acquisition.
• 3Q potential IPR&D impactApproximately $290mn-$320mn pre-tax; approximately $1.75-$1.95 per shareRelated to milestones and transactions that have not yet been completed.
• APLS acquisition financingApproximately $3.6bn cash + approximately $2bn debtThe company expects financing costs and foregone interest income of approximately $120mn-$130mn in 2026 and 2027.
• APLS synergiesAt least $150mn in cost savings entering 2027Goldman Sachs believes the transaction could be accretive to non-GAAP EPS beginning in 2027.
• 2027 non-GAAP EPS forecast$15.23Approximately 30% growth versus Goldman Sachs' FY26 forecast of $11.47, approaching FY25's $15.28.
• FY26 MS revenue forecast$2.75bn, -17% YoYReflects accelerating erosion after Tecfidera lost exclusivity in the EU and biosimilar competition for Tysabri.
• Syfovre peak sales assumption$937mnGoldman Sachs' model estimates that Syfovre represents approximately $15 per share of value.
• ANNX competition scenario impact5.5% DCF decline; approximately 8% impact on the current share priceIf ANNX's geographic atrophy Ph3 data are successful, BIIB shares could come under pressure.
• Price target$27112-month price target based on a 100% DCF analysis.
• Latest closing price in the table$199.95Closing price corresponding to 20-Jul-26 in the historical price target table.

Impact & implications

The investment implication is that BIIB's near-term earnings may not be the sole driver; the market is more likely to reassess the value of the portfolio around 2027 earnings recovery, realization of APLS synergies, the Leqembi commercialization inflection point, and multiple Ph3 readouts. If APLS integration proceeds smoothly and Leqembi and key pipeline programs advance as expected, there is substantial upside between the price target and the current share price; however, faster MS deterioration or competitive clinical data more favorable than Syfovre could weaken valuation support.

Risks

• MS franchise revenue could decline faster than expected, particularly following Tecfidera's loss of exclusivity in the EU and amid biosimilar competition for Tysabri.
• Successful ANNX geographic atrophy Ph3 data could weaken Syfovre's commercial and valuation contribution.
• Leqembi's commercial opportunity could be affected by competitive data, reimbursement progress, physician adoption, and treatment-pathway bottlenecks.
• diranersen Ph2 data did not meet the primary endpoint; questions remain regarding the low-dose cohort results, the relationship between tau reduction and clinical benefit, sample size, and baseline imbalances.
• Clinical, regulatory, or commercialization failures in key pipeline programs could reduce sales forecasts.
• Failure of intellectual property protection or patent expirations could affect long-term revenue and royalty income.

What to watch

• How management incorporates the APLS transaction, synergies, and expense impacts into full-year revenue and EPS guidance during the 2Q earnings call.
• APLS integration progress, Syfovre and Empaveli revenue contributions, and realization of cost savings in 2027.
• ANNX's geographic atrophy Ph3 data expected in 2H and their impact on Syfovre's competitive landscape.
• litifilimab SLE Ph3 data in 2H and CLE Ph3 data in 1H27.
• felzartamab AMR Ph3 data in 2027 and progress in IgAN and PMN indications.
• Reimbursement, adoption, blood-based diagnostic penetration, and 2027 sales acceleration for subcutaneous Leqembi induction and maintenance dosing.
• Details of the diranersen Ph3 design and long-term Ph2 updates around YE26.
• salanersen SMA Ph3 data around 2028 and product transition ahead of Spinraza patent expirations in 2030-2034.